ATE423559T1 - Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren - Google Patents

Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Info

Publication number
ATE423559T1
ATE423559T1 AT02717766T AT02717766T ATE423559T1 AT E423559 T1 ATE423559 T1 AT E423559T1 AT 02717766 T AT02717766 T AT 02717766T AT 02717766 T AT02717766 T AT 02717766T AT E423559 T1 ATE423559 T1 AT E423559T1
Authority
AT
Austria
Prior art keywords
combination therapy
ppar modulators
absorption inhibitors
glucose absorption
ppar
Prior art date
Application number
AT02717766T
Other languages
English (en)
Inventor
Jacqueline Bussolari
Xiaoli Chen
Bruce Conway
Keith Demarest
Hamish Ross
Rafael Severino
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of ATE423559T1 publication Critical patent/ATE423559T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT02717766T 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren ATE423559T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28142901P 2001-04-04 2001-04-04

Publications (1)

Publication Number Publication Date
ATE423559T1 true ATE423559T1 (de) 2009-03-15

Family

ID=23077253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717766T ATE423559T1 (de) 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Country Status (11)

Country Link
US (3) US20030045553A1 (de)
EP (2) EP1381361B1 (de)
JP (1) JP4590159B2 (de)
CN (1) CN100577175C (de)
AT (1) ATE423559T1 (de)
CA (1) CA2442917C (de)
DE (1) DE60231295D1 (de)
ES (1) ES2321815T3 (de)
MY (1) MY180762A (de)
TW (1) TWI330084B (de)
WO (1) WO2002080936A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392326B1 (de) 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
EP1388352A1 (de) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
RU2005140949A (ru) * 2003-06-27 2007-08-10 Д-р Редди`с Ресерч Фаундэйшн (IN) Композиции, включающие балаглитазон и дополнительные противодиабетические соединения
EP1662906A1 (de) * 2003-09-23 2006-06-07 DSM IP Assets B.V. Zusammensetzungen für die behandlung und vorbeugung von diabetes mellitus
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20080274193A1 (en) * 2004-01-23 2008-11-06 Japan Science And Technology Agency Retinoic Acid-Containing Antidiabetic Agent
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
US9421175B2 (en) 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
CA2572793C (en) * 2004-07-21 2015-11-03 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
JP2008531707A (ja) * 2005-03-03 2008-08-14 スミスクライン ビーチャム コーポレーション 医薬品
WO2007038670A2 (en) * 2005-09-30 2007-04-05 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
EP1785133A1 (de) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US8666671B2 (en) * 2007-07-05 2014-03-04 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
WO2009096455A1 (ja) 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
MY155418A (en) * 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
PL2601949T3 (pl) * 2009-04-16 2015-04-30 Taisho Pharmaceutical Co Ltd Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny
JP5902619B2 (ja) * 2009-07-10 2016-04-13 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｘｒアゴニスト化合物および方法
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 ｓｇｌｔ-1/ｓｇｌｔ-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
AU2010310956B2 (en) 2009-11-02 2014-05-08 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
NO2543357T3 (de) * 2011-07-07 2018-08-18
US9451987B2 (en) 2011-11-16 2016-09-27 K2M, Inc. System and method for spinal correction
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
ES2625548T3 (es) 2012-06-04 2017-07-19 DiaMedica Therapeutics Inc. Isoformas de glicosilación de la calicreína-1 tisular humana
CN102727477B (zh) * 2012-06-14 2014-07-16 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治糖尿病药物中的应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CA3054962A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
US20210059997A1 (en) * 2017-12-28 2021-03-04 University Of Fukui Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops
CN111437393B (zh) * 2020-04-30 2021-03-02 深圳微芯生物科技股份有限公司 用于糖尿病及其并发症治疗的联合用药及其药物组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) * 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2795162B2 (ja) 1993-02-18 1998-09-10 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2906978B2 (ja) 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
EP1426048A3 (de) 1995-09-18 2004-06-16 Ligand Pharmaceuticals, Inc. Behandlung der Hypertriglyceridämie mit RXR Agonisten in Kombination mit einem PPARgamma Agonist
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
CN1230114A (zh) * 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法
ATE216704T1 (de) * 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4100734B2 (ja) 1997-04-30 2008-06-11 Ｓａｂｉｃイノベーティブプラスチックスジャパン合同会社 熱可塑性樹脂組成物
EP0975343A1 (de) 1997-06-18 2000-02-02 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und alpha-glukosidaseinhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
CA2351727C (en) * 1998-11-20 2008-09-23 Mitsubishi Chemical Corporation Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
US6337426B1 (en) 1998-11-23 2002-01-08 Nalco/Exxon Energy Chemicals, L.P. Antifoulant compositions and processes
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU4649600A (en) 1999-04-22 2000-11-10 Joel F. Habener Bridge-1, a transcription factor
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ES2216937T3 (es) 1999-08-31 2004-11-01 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol, composiciones medicinales que los contienen e intermedios obtenidos durante su preparacion.
AU6949900A (en) 1999-08-31 2001-03-26 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
KR100518142B1 (ko) 1999-11-10 2005-10-04 다케다 야쿠힌 고교 가부시키가이샤 혈당저하 및 지질혈저하 활성을 갖는 5-원ｎ-헤테로고리형 화합물
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
AU2002253838B2 (en) * 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
JP4035052B2 (ja) * 2000-12-28 2008-01-16 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
EP1392326B1 (de) * 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Also Published As

Publication number Publication date
US8278268B2 (en) 2012-10-02
ES2321815T3 (es) 2009-06-12
EP1381361A1 (de) 2004-01-21
US20030199557A1 (en) 2003-10-23
EP1381361B1 (de) 2009-02-25
JP2004529915A (ja) 2004-09-30
US20080096802A1 (en) 2008-04-24
EP2065044A1 (de) 2009-06-03
CN1568190A (zh) 2005-01-19
WO2002080936A1 (en) 2002-10-17
TWI330084B (en) 2010-09-11
DE60231295D1 (de) 2009-04-09
CA2442917A1 (en) 2002-10-17
JP4590159B2 (ja) 2010-12-01
US20030045553A1 (en) 2003-03-06
CN100577175C (zh) 2010-01-06
CA2442917C (en) 2011-02-01
MY180762A (en) 2020-12-08

Similar Documents

Publication Publication Date Title
ATE423559T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
ATE442148T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
PT1333887E (pt) Metodo de tratamento de desordens musculares
PL374865A1 (en) Treatment of tnf alpha related disorders
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
IL194950A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
NO20053041D0 (no) Behandling av diabetes.
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ATE410165T1 (de) Nociceptin-analoga
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20022087L (no) Fremgangsmåte for behandling av diabetes
ATE350385T1 (de) Neue aryl fructose-1,6-bisphosphatase inhibitoren
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
NO20045554L (no) Fremgangsmate for behandling av diabetes
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
FI20011298L (fi) Puunkäsittelyliuos ja menetelmä puun säilyvyyden parantamiseksi
SE0103276D0 (sv) Anordning för administrering av salva till en hudyta
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties